HONG KONG – Japanese and French researchers have discovered the cellular signaling mechanism whereby the balance of disturbed inhibitory synaptic connections is restored, which could have important implications for the management of neurological disorders such as epilepsy and possibly even autism, they reported in the Dec. 17, 2015, issue of Cell Reports.
Dimerix Ltd., of Melbourne, Australia, added Liz Jazwinska to its board. Jazwinska has more than 25 years of experience in R&D management and drug portfolio business development.
SHANGHAI – Astrazeneca plc, of London, is betting that a "made-in-China" label will shave years off the usual CFDA review and approval timelines that imported drugs face and will get its pipeline of therapeutics to Chinese patients much faster.
SHANGHAI – In China, it is often said there is more venture capital (VC) money sloshing around than there are good assets, or companies in which to invest. That poses an interesting conundrum for VCs: They see the sizable money-making potential in China – given the increasing market demands of a rapidly aging population with significant unmet medical needs – but face a lack of readymade investment vehicles to fund.
HONG KONG – Even as Asian markets wobble and investors scrutinize every move, Chinese drugmaker Yichang HEC Changjiang Pharmaceutical Co. Ltd., which focuses on developing, manufacturing and selling antiviral medicines, launched an IPO in Hong Kong Monday looking to raise as much as HK$1.67 billion (US$215 million).
HONG KONG – The chill of a wide-ranging anti-corruption campaign in China that has led to some very high-profile arrests spread with news that Guo Guangchang, the chairman of Fosun International Ltd., may have been snared in a corruption investigation. Shares of its subsidiary, Fosun Pharmaceutical Group Co. Ltd. (HKEX:2196, SS:600196), plunged more than 12 percent Monday on the Hong Kong stock exchange and about 4 percent in Shanghai.
HONG KONG – Marking another step forward for South Korea's leading biosimilar developer, the Ministry of Food and Drug Safety (MFDS) approved domestic sales of Samsung Bioepis Co. Ltd.'s Renflexis (infliximab), a biosimilar of Johnson & Johnson's Remicade (infliximab). This is the second marketing approval for the company this year.
Akebia Therapeutics Inc.'s president and CEO, John Butler, told investors during a Monday conference call that it was the company's goal to find a Japanese partner for phase III-ready vadadustat, an oral therapy for the treatment of anemia related to chronic kidney disease (CKD), by the end of 2015. With two weeks to spare, the Cambridge, Mass.-based firm inked a deal with Mitsubishi Tanabe Pharma Corp. (MTPC) that Butler said hits the target, "both strategically and financially."
SHANGHAI – Wuxi Pharmatech (Cayman) Inc., a new breed of contract R&D organization, has completed the privatization process, requesting its stocks to stop trading on the New York Stock Exchange on Dec. 10. Wuxi's chairman and chief executive, Ge Li, along with a consortium of private-equity investors paid $3.3 billion in cash to complete the deal. Wuxi first listed in the U.S. in 2007.
RSS